Serveur d'exploration sur la maladie de Parkinson

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Treatment of depressive symptoms in Parkinson’s disease

Identifieur interne : 000110 ( Main/Exploration ); précédent : 000109; suivant : 000111

Treatment of depressive symptoms in Parkinson’s disease

Auteurs : P. Barone [Italie]

Source :

RBID : ISTEX:1278AA935EF43A8019053A48CE3519599B29815B

English descriptors

Abstract

Significant depressive disorders are present in approximately 30–40% of patients with Parkinson’s disease (PD). Depressive symptoms are correlated with poor health‐related quality‐of‐life (HRQoL) scores, and are the major determinant of HRQoL. Studies that have evaluated pharmacotherapy for depressive symptoms in PD have shown that there is substantial variability in outcomes. Recently, two double‐blind, placebo‐controlled studies showed the superiority of nortriptyline and desipramine versus placebo and selective serotonin reuptake inhibitors. The antidepressant effects of dopamine agonists have been explored mainly in open and non‐controlled studies. In a 14‐week randomized trial comparing pramipexole with sertraline in depressed patients without motor complications, the Hamilton Depression Rating Scale score decreased in both groups; however, in the pramipexole group, the proportion of patients who recovered was significantly higher. Recently, in the first 12‐week double‐blind placebo‐controlled clinical trial in PD patients without motor fluctuations on stable levodopa treatment, pramipexole reduced depressive symptoms as measured by Beck Depression Inventory score, with a significant difference in efficacy in favour of pramipexole. These data suggest that pramipexole might represent an alternative to antidepressant drugs to treat depressive symptoms in PD without adding the risk of antidepressant adverse events, and avoid polypharmacy.

Url:
DOI: 10.1111/j.1468-1331.2010.03325.x


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Treatment of depressive symptoms in Parkinson’s disease</title>
<author>
<name sortKey="Barone, P" sort="Barone, P" uniqKey="Barone P" first="P." last="Barone">P. Barone</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1278AA935EF43A8019053A48CE3519599B29815B</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1111/j.1468-1331.2010.03325.x</idno>
<idno type="url">https://api.istex.fr/document/1278AA935EF43A8019053A48CE3519599B29815B/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">001C17</idno>
<idno type="wicri:Area/Main/Curation">001947</idno>
<idno type="wicri:Area/Main/Exploration">000110</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Treatment of depressive symptoms in Parkinson’s disease</title>
<author>
<name sortKey="Barone, P" sort="Barone, P" uniqKey="Barone P" first="P." last="Barone">P. Barone</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurological Sciences, University of Napoli Federico II‐IDC Hermitage Capodimonte, Naples</wicri:regionArea>
<wicri:noRegion>Naples</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">European Journal of Neurology</title>
<idno type="ISSN">1351-5101</idno>
<idno type="eISSN">1468-1331</idno>
<imprint>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2011-03">2011-03</date>
<biblScope unit="volume">18</biblScope>
<biblScope unit="supplement">s1</biblScope>
<biblScope unit="page" from="11">11</biblScope>
<biblScope unit="page" to="15">15</biblScope>
</imprint>
<idno type="ISSN">1351-5101</idno>
</series>
<idno type="istex">1278AA935EF43A8019053A48CE3519599B29815B</idno>
<idno type="DOI">10.1111/j.1468-1331.2010.03325.x</idno>
<idno type="ArticleID">ENE3325</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1351-5101</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Parkinson's disease</term>
<term>antidepressant therapy</term>
<term>depression</term>
<term>non‐motor symptoms</term>
<term>pramipexole</term>
<term>quality of life</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Significant depressive disorders are present in approximately 30–40% of patients with Parkinson’s disease (PD). Depressive symptoms are correlated with poor health‐related quality‐of‐life (HRQoL) scores, and are the major determinant of HRQoL. Studies that have evaluated pharmacotherapy for depressive symptoms in PD have shown that there is substantial variability in outcomes. Recently, two double‐blind, placebo‐controlled studies showed the superiority of nortriptyline and desipramine versus placebo and selective serotonin reuptake inhibitors. The antidepressant effects of dopamine agonists have been explored mainly in open and non‐controlled studies. In a 14‐week randomized trial comparing pramipexole with sertraline in depressed patients without motor complications, the Hamilton Depression Rating Scale score decreased in both groups; however, in the pramipexole group, the proportion of patients who recovered was significantly higher. Recently, in the first 12‐week double‐blind placebo‐controlled clinical trial in PD patients without motor fluctuations on stable levodopa treatment, pramipexole reduced depressive symptoms as measured by Beck Depression Inventory score, with a significant difference in efficacy in favour of pramipexole. These data suggest that pramipexole might represent an alternative to antidepressant drugs to treat depressive symptoms in PD without adding the risk of antidepressant adverse events, and avoid polypharmacy.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Italie</li>
</country>
</list>
<tree>
<country name="Italie">
<noRegion>
<name sortKey="Barone, P" sort="Barone, P" uniqKey="Barone P" first="P." last="Barone">P. Barone</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000110 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000110 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:1278AA935EF43A8019053A48CE3519599B29815B
   |texte=   Treatment of depressive symptoms in Parkinson’s disease
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024